Literature DB >> 97791

Gentamicin-resistant gram-negative bacilli in hospital patients. Part I. Preliminary epidemiological assessment.

C S Block.   

Abstract

Gentamicin-resistant Gram-negative bacilli (GRNB) have been isolated from specimens received from 23 hospitals in and around Johannesburg. Most isolates are fermentative in nature. A pilot survey among inpatients at the Johannesburg Hospital revealed an intestinal carriage prevalence of 14,3%. A prospective study of intestinal acquisition showed that GRNB are acquired in hospital, and that colonization is associated with prior antibacterial therapy. Analysis of clinical specimens received from the Johannesburg Hospital from 1 July to 30 September 1976 has indicated that intensive care and urology units are worst affected. An assessment of the overall prevalence of GRNB in October 1976 revealed that 16,1% of all Gram-negative bacilli were resistant to gentamicin. Major contributing factors are the widespread use of systemic aminoglycoside antibiotics, and a high rate of cross-contamination. Measures aimed at minimizing these factors have been introduced by the Johannesburg Hospital administration.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 97791

Source DB:  PubMed          Journal:  S Afr Med J


  3 in total

1.  Resistance of Escherichia coli in faeces and the use of antimicrobial agents in the treatment of hospital patients.

Authors:  J E Degener; A C Smit; M F Michel; H A Valkenburg; L Muller
Journal:  J Hyg (Lond)       Date:  1983-12

2.  Comparative in vitro appraisal of piperacillin, including its activity against Salmonella typhi.

Authors:  R G Robinson; J Saunders; R Cassel; C S Block; H J Koornhof
Journal:  Antimicrob Agents Chemother       Date:  1980-10       Impact factor: 5.191

3.  Dissemination of an antibiotic resistance plasmid in hospital patient flora.

Authors:  T F O'Brien; D G Ross; M A Guzman; A A Medeiros; R W Hedges; D Botstein
Journal:  Antimicrob Agents Chemother       Date:  1980-04       Impact factor: 5.191

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.